Mammalian Cell Banking Market Poised to Hit $4.78 Billion by 2029 with Accelerating Growth Trends

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Mammalian Cell Banking Market Size Growth Forecast: What to Expect by 2025?
The market size of mammalian cell banking has notably expanded in the past few years. A projected increase from $2.82 billion in 2024 to $3.14 billion in 2025 occurs with a compound annual growth rate (CAGR) of 11.5%. The historical growth can be accounted for by several factors including an escalated demand for monoclonal antibodies, heightened investments in biopharmaceutical R&D, intensified regulatory requirements for GMP compliance, a growing shift towards the use of mammalian expression systems, and a surge in the authorization of biologic drugs.

How Will the Mammalian Cell Banking Market Size Evolve and Grow by 2029?
The market for mammalian cell banking is projected to witness swift expansion in the forthcoming years, reaching $4.79 billion in 2029 at a compound annual growth rate of 11.1%. The escalation in the projected period can be linked to the increasing need for cell and gene therapies, the prevalent acceptance of personalized medicine, amplified investment in biomanufacturing structures, advances in biosimilar and biobetter research, coupled with an uptick in pandemic readiness and vaccine development. Key market trends for the forecast period encompass the incorporation of automation and digital tracking, enhanced cell culture technology, advancements in regenerative medicine, the emergence of serum-free and protein-free media, as well as the evolution in cryopreservation and analytical technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report

What Drivers Are Propelling the Growth of Mammalian Cell Banking Market Forward?
The mammalian cell banking market is expected to grow, driven by the increasing need for cell-based therapies. These therapies utilize alive, often modified or engineered cells, to restore, substitute, or regenerate damaged tissues and organs, providing target-specific solutions for numerous diseases. As the occurrence of chronic and rare diseases increases, so does the need for more efficient and focused treatment methods. Mammalian cell banking offers a reliable, regulated source of high-grade cells, ensuring uniformity, safety, and scalability in the progression and production of regenerative treatments. The American Society of Gene and Cell Therapy reported in April 2024 that there has been a growth in the number of therapies across all clinical pipeline phases since 2023, with Phase I exhibiting an increase of 11% since before the fourth quarter of 2022. Therefore, the escalating need for cell-based therapies is propelling the mammalian cell banking market. The escalation in the prevalence of chronic diseases is also playing a central role in the growth of the mammalian cell banking market. These diseases are protracted medical conditions that usually need continuous management. With the world's population aging, chronic diseases are becoming more common, especially in older individuals who are more prone to health conditions requiring long-term management. Mammalian cell banking aids the management of chronic diseases by providing a steady supply of high-grade cells used to develop steady cell-based therapies and biologics. The International Diabetes Federation reported in April 2025 that there were around 589 million adults aged 20-79 living with diabetes in 2024, and this number is expected to surge to 853 million by 2050. Therefore, the growth in chronic diseases is also driving the mammalian cell banking market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28262&type=smp

Which Emerging Trends Are Transforming the Mammalian Cell Banking Market in 2025?
Leading corporations in the mammalian cell banking sector are concentrating their efforts on creating cutting-edge solutions such as distinctive stable cell line systems. These systems aim to improve cell line productivity, maintain genetic stability over an extended period, and simplify biopharmaceutical production procedures. Stable cell line systems utilize genetically modified mammalian cells, that are designed to continuously produce a specific protein or medicinal molecule across numerous generations, with a strong focus on genetic stability and consistency. In August 2024, WuXi Biologics, a biopharmaceutical business located in China, launched the WuXia293 Stable platform. This advanced stable cell line system, based on HEK293, has been developed specifically for the creation and manufacture of biologic molecules that are particularly challenging to express. With the help of proprietary mammalian cell line expansion technology, this platform guarantees stable expression and uniform quality over an extended series of cell passages. The WuXia293 Stable platform addresses problems associated with low yield and quality issues seen in traditional CHO cell systems, delivering high protein titers, enhanced human-like glycosylation, and easily scalable production ideal for clinical and commercial manufacturing.

What Are the Key Segments in the Mammalian Cell Banking Market?
The mammalian cell banking market covered in this report is segmented as

1) By Product Type: Master Cell Bank, Working Cell Bank
2) By Cell Type: Chinese Hamster Ova*ry Mammalian Cell Banking (CHO), Baby Hamster Kidney (BHK), Non-Secreting 0 (NS0), YB2/0 And P2/0, Human Embryonic Kidney 293 (HEK293) And Derivatives, Henrietta Lacks (HELA)
3) By Storage Type: Liquid Nitrogen, Controlled Rate Freezer, Flash Freezing
4) By Application: Drug Development, Vaccine Production, Gene Therapy, Monoclonal Antibody Production
5) By End User: Academic And Research Laboratories, Biopharmaceutical Companies, Contract Research Organizations (CROs)

Subsegments:
1) By Master Cell Bank: Recombinant Cell Lines, Hybridoma Cell Lines, Primary Cell Lines, Genetically Engineered Cell Lines, Viral Vector Producing Cell Lines
2) By Working Cell Bank: Current Good Manufacturing Practice (CGMP)-Compliant Cell Banks, Research-Grade Cell Banks, Clinical Trial Cell Banks, Commercial Production Cell Banks, Stability Testing Cell Banks

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28262&type=smp

Who Are the Key Players Shaping the Mammalian Cell Banking Market's Competitive Landscape?
Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S.A., Samsung Biologics Co. Ltd., CMIC Holdings Co. Ltd., WuXi Biologics Inc., Fujifilm Diosynth Biotechnologies Inc., Evotec SE, AGC Biologics Inc., CordenPharma International GmbH, GenScript ProBio Co. Ltd., Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, BioVectra Inc., Polpharma Biologics S.A., and Abzena plc.

What Geographic Markets Are Powering Growth in the Mammalian Cell Banking Market?
North America was the largest region in the mammalian cell banking market in 2024. The regions covered in mammalian cell banking report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28262

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.